Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | ADK | P55263 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8797054 | 0.98 | NISCH (0.61) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL7313533 | 0.84 | CYP1A2 (0.54) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL722191 | 0.84 | NISCH (0.78) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL862114 | 0.81 | NISCH (0.75) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL23036850 | 0.78 | NISCH (0.52) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL9719773 | 0.77 | NISCH (1.00) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL8901 | 0.77 | NISCH (1.00) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL1688472 | 0.77 | NISCH (0.68) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL965214 | 0.76 | NISCH (0.60) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL11072040 | 0.76 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-04-25 | — | — | US | claimed |
| WO-2023230217-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | WO | claimed |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | claimed |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | claimed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | claimed |
| EP-4267570-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | claimed |
| EP-4267568-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | claimed |
| CN-116710447-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-09-05 | — | — | CN | claimed |
| US-20230220161-A1 | POLYIMIDE PRECURSOR PREPARED BY USING POLYCYCLIC MONOMER INCLUDING TRIFLUOROMETHYL GROUP AND FLEXIBLE POLYIMIDE OBTAINED BY USING THE SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-07-13 | — | — | US | claimed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | claimed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | claimed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | claimed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | claimed |
| EP-0728145-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | Ciba-Geigy Japan Limited (JP) | 1996-08-28 | — | — | EP | claimed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | claimed |
| WO-1995012611-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | JAPAT LTD. (CH) | 1995-05-11 | — | — | WO | claimed |
| US-5246958-A | Thiocarbamoylacetonitriles | MITSUBISHI KASEI CORPORATION (JP) | 1993-09-21 | — | — | US | claimed |
| EP-0279787-A1 | Pharmaceutical compositions with synergistic antisecretory action for the healing of gastroduodenal ulcer | ISTITUTO DE ANGELI S.p.A. (IT) | 1988-08-24 | — | — | EP | claimed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | claimed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | MPO, SSB, SGMS2 | NISCH 282/4885MTOR 1609/4885ADK 2181/4885 |
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS3BP | NISCH 4037/4885MTOR 1114/4885ADK 2239/4885 |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | CGAS, GLS2, GBA3 | NISCH 3138/4885MTOR 1775/4885ADK 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.